Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
The subjects in this study will be subjects with central-involved DME (CI-DME). Both treatment-naïve and previously treated subjects will be included.~Inclusion Criteria:~* Written informed consent obtained from the subject prior to screening procedures~* Male or female aged 18 years or older at the time of signing the informed consent~* Type 1 or type 2 diabetes~* BCVA ETDRS letter score ≥ 39 in the study eye~* CI-DME with CST of ≥ 300µm in men (or equivalent in women), measured from RPE to ILM inclusively, on SD-OCT, in the study eye~* BCVA ETDRS letter score ≥ 34 in the fellow eye~Exclusion Criteria:~* Macular edema due to causes other than DME in the study eye~* Concurrent disease in the study eye, other than DME, that could require medical or surgical intervention during the study period or could confound interpretation of the results~* Any condition in the study eye that could confound the ability to detect the efficacy of the investigational medicinal product~* Previous confounding medications / interventions, or their planned administration during the study~* Presence of iris neovascularisation in the study eye~* Uncontrolled glaucoma in the study eye~* Previously received THR-687 or any other experimental therapy for DME, in either eye~* Any active or suspected ocular or periocular infection, or active intraocular inflammation, in either eye~* Untreated Diabetes~* Glycated haemoglobin A (HbA1c) \> 12%~* Uncontrolled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part A, THR-687 1.2 mg (Type: EXPERIMENTAL): None
- Part A, THR-687 2.0mg (Type: EXPERIMENTAL): None
- Part B, treatment naïve subjects, THR-687 selected dose level (Type: EXPERIMENTAL): Due to the discontinuation of the study after Part A, the dose level for Part B has not been selected
- Part B, treatment naïve subjects, aflibercept 2.0mg (Type: ACTIVE_COMPARATOR): None
- Part B, previously treated subjects, THR-687 selected dose level (Type: EXPERIMENTAL): Due to the discontinuation of the study after Part A, the dose level for Part B has not been selected
- Part B, previously treated subjects, aflibercept 2.0mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).